Skip to main content
NVDA+0.54%AAPL-0.85%GOOGL-1.55%MSFT-0.95%AMZN-1.85%TSM-0.93%SPCX-1.82%META+0.95%AVGO-0.97%TSLA+0.33%SKHY-0.16%BRK-B+0.03%LLY+0.57%MU+0.66%JPM-1.37%WMT-0.14%AMD+2.15%V-0.43%XOM+2.44%JNJ-0.92%ASMLa-1.03%0700.HK+1.90%MA-0.60%INTC+1.67%ABBV+0.40%1398.HK-2.09%CSCO+0.72%CVX+1.91%BAC-0.28%ORCL-0.81%COST-1.14%KO-1.04%DELL+3.73%CAT-0.28%HSBA.L-2.15%0005.HK-3.21%PG+0.39%UNH-1.61%LRCX-2.21%AP2d-2.17%AMAT-1.12%1816.HK-0.46%3988.HK-2.13%NFLX-2.80%GE-2.81%MS-1.89%0857.HK+0.60%HD-1.46%PM-0.25%0939.HK-2.83%USDJPY+1.03%NZDUSD-0.95%CHFJPY+0.78%USDTHB+0.72%GBPJPY+0.70%CADJPY+0.69%GBPNZD+0.65%NZDCHF-0.62%NZDCAD-0.62%AUDUSD-0.57%EURJPY+0.52%EURUSD-0.48%EURNZD+0.48%AUDJPY+0.48%PLNJPY+0.45%NOKJPY+0.44%GBPTRY+0.41%AUDNZD+0.39%USDCAD+0.34%NZDMXN-0.33%USDCHF+0.33%SGDJPY+0.32%GBPHKD+0.32%GBPUSD-0.31%GBPMXN-0.28%USDTRY+0.25%GBPAUD+0.24%AUDCHF-0.22%USDSEK+0.21%AUDCAD-0.21%USDSGD+0.19%EURCAD-0.17%EURSEK+0.16%USDILS+0.16%NZDSGD-0.16%EURGBP-0.15%EURSGD+0.14%CHFNOK-0.14%GBPZAR-0.13%EURCHF-0.13%EURCZK+0.11%EURAUD+0.10%USDNOK+0.09%AUDDKK-0.08%NZDJPY+0.08%USDCNH+0.08%GBPSGD+0.07%USDPLN+0.07%AUDSGD+0.07%EURZAR-0.06%AUDNOK-0.05%USDDKK+0.04%EURHKD-0.04%USDCOP-0.04%GBPCAD+0.03%EURNOK+0.03%CHFSGD-0.03%USDMXN+0.02%USDHKD+0.02%CADCHF-0.02%EURPLN+0.02%USDZAR-0.01%CHFSEK-0.01%EURDKK-0.01%GBPCHF0.00%EURCNH0.00%USOIL+2.62%W1+1.91%UKOIL+1.72%XNGUSD+1.25%SUGAR-1.10%C1+1.08%COCOA-1.08%COFFEE-1.08%S1+0.93%HG1+0.43%XAUUSD-0.37%GAUUSD-0.37%BTCUSD-2.72%ETHUSD-3.95%USDTUSD-0.03%XRPUSD-2.34%SOLUSD-3.22%TRXUSDT-0.50%ZECUSDT-3.85%DOGEUSD-2.21%XMRUSDT+0.72%LINKUSD-2.58%XLMUSD+0.69%BCHUSDT-1.30%UNIUSD-3.15%LTCUSD-2.58%HBARUSDT-0.05%TONUSD+26.79%SUIUSD-2.54%TAOUSDT-3.24%AAVEUSD-2.35%DOTUSDT-2.11%ICPUSDT-7.14%ONDOUSDT-3.23%WLDUSDT-1.56%ARBUSDT+5.17%ATOMUSDT-1.85%JUPUSDT-4.30%INJUSDT-9.56%STXUSDT-3.11%FETUSDT-4.35%PYTHUSDT-4.13%TIAUSDT-6.14%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-1.70%GRTUSDT-4.12%WIFUSDT-4.80%POLUSDT+0.66%IOTAUSDT-5.86%AXSUSDT-3.20%FARTCOINUSDT-1.63%EOSUSDT-4.45%DYDXUSDT-5.96%ORDIUSDT-2.01%GALAUSDT-1.47%NOTUSDT-0.18%RONINUSDT-14.59%NVDA+0.54%AAPL-0.85%GOOGL-1.55%MSFT-0.95%AMZN-1.85%TSM-0.93%SPCX-1.82%META+0.95%AVGO-0.97%TSLA+0.33%SKHY-0.16%BRK-B+0.03%LLY+0.57%MU+0.66%JPM-1.37%WMT-0.14%AMD+2.15%V-0.43%XOM+2.44%JNJ-0.92%ASMLa-1.03%0700.HK+1.90%MA-0.60%INTC+1.67%ABBV+0.40%1398.HK-2.09%CSCO+0.72%CVX+1.91%BAC-0.28%ORCL-0.81%COST-1.14%KO-1.04%DELL+3.73%CAT-0.28%HSBA.L-2.15%0005.HK-3.21%PG+0.39%UNH-1.61%LRCX-2.21%AP2d-2.17%AMAT-1.12%1816.HK-0.46%3988.HK-2.13%NFLX-2.80%GE-2.81%MS-1.89%0857.HK+0.60%HD-1.46%PM-0.25%0939.HK-2.83%USDJPY+1.03%NZDUSD-0.95%CHFJPY+0.78%USDTHB+0.72%GBPJPY+0.70%CADJPY+0.69%GBPNZD+0.65%NZDCHF-0.62%NZDCAD-0.62%AUDUSD-0.57%EURJPY+0.52%EURUSD-0.48%EURNZD+0.48%AUDJPY+0.48%PLNJPY+0.45%NOKJPY+0.44%GBPTRY+0.41%AUDNZD+0.39%USDCAD+0.34%NZDMXN-0.33%USDCHF+0.33%SGDJPY+0.32%GBPHKD+0.32%GBPUSD-0.31%GBPMXN-0.28%USDTRY+0.25%GBPAUD+0.24%AUDCHF-0.22%USDSEK+0.21%AUDCAD-0.21%USDSGD+0.19%EURCAD-0.17%EURSEK+0.16%USDILS+0.16%NZDSGD-0.16%EURGBP-0.15%EURSGD+0.14%CHFNOK-0.14%GBPZAR-0.13%EURCHF-0.13%EURCZK+0.11%EURAUD+0.10%USDNOK+0.09%AUDDKK-0.08%NZDJPY+0.08%USDCNH+0.08%GBPSGD+0.07%USDPLN+0.07%AUDSGD+0.07%EURZAR-0.06%AUDNOK-0.05%USDDKK+0.04%EURHKD-0.04%USDCOP-0.04%GBPCAD+0.03%EURNOK+0.03%CHFSGD-0.03%USDMXN+0.02%USDHKD+0.02%CADCHF-0.02%EURPLN+0.02%USDZAR-0.01%CHFSEK-0.01%EURDKK-0.01%GBPCHF0.00%EURCNH0.00%USOIL+2.62%W1+1.91%UKOIL+1.72%XNGUSD+1.25%SUGAR-1.10%C1+1.08%COCOA-1.08%COFFEE-1.08%S1+0.93%HG1+0.43%XAUUSD-0.37%GAUUSD-0.37%BTCUSD-2.72%ETHUSD-3.95%USDTUSD-0.03%XRPUSD-2.34%SOLUSD-3.22%TRXUSDT-0.50%ZECUSDT-3.85%DOGEUSD-2.21%XMRUSDT+0.72%LINKUSD-2.58%XLMUSD+0.69%BCHUSDT-1.30%UNIUSD-3.15%LTCUSD-2.58%HBARUSDT-0.05%TONUSD+26.79%SUIUSD-2.54%TAOUSDT-3.24%AAVEUSD-2.35%DOTUSDT-2.11%ICPUSDT-7.14%ONDOUSDT-3.23%WLDUSDT-1.56%ARBUSDT+5.17%ATOMUSDT-1.85%JUPUSDT-4.30%INJUSDT-9.56%STXUSDT-3.11%FETUSDT-4.35%PYTHUSDT-4.13%TIAUSDT-6.14%SEIUSDT-2.47%IMXUSDT-1.81%OPUSDT-1.70%GRTUSDT-4.12%WIFUSDT-4.80%POLUSDT+0.66%IOTAUSDT-5.86%AXSUSDT-3.20%FARTCOINUSDT-1.63%EOSUSDT-4.45%DYDXUSDT-5.96%ORDIUSDT-2.01%GALAUSDT-1.47%NOTUSDT-0.18%RONINUSDT-14.59%
RT

Rapport Therapeutics, Inc. Common Stock (RAPP)

NASDAQ • Healthcare

$44
+$0.38 (+0.9%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$44.3
Previous Close$44
Day Range$43.36 - $44.9
Avg. Volume (3M)285.6K
Market Cap$2B
52 Week Range
$23.75$52.93
Next EarningsIn 51 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$20M
Net Income (TTM)
-$137.1M
EPS (TTM)
-$3.04
ROA (TTM)
-29.88%
Current Ratio
15.72

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-10.8%Q1 2026-$0.72
+25.0%Q2 2026-$0.42
-6.2%Q3 2026-$1.19
Next

Nov 5

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -6.2%

Rapport Therapeutics’ second fiscal quarter of 2026 results (based on preliminary figures reported August 5, 2026) missed expectations on EPS, with EPS of -$1.19 trailing the -$1.12 estimate by -$0.07, as the CNS-focused biotech continued to run operating losses tied to advancing its pipeline, including the RAP-219 program for indications such as epilepsy and pain. The company posted a GAAP net loss of roughly $56.6 million, down 111.8% year over year from a net loss of about $26.7 million a year ago, while operating income was about -$60.8 million. On the bottom line, EPS was down 58.7% from -$0.75 a year earlier. Cash generation remained negative, with operating cash flow of roughly -$41.5 million during the quarter. For the next period, consensus calls for EPS of -$1.21.

View full earnings history

About Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. is a small-cap biotechnology company listed on the NASDAQ as RAPP that discovers and develops small-molecule medicines for central nervous system disorders. The company works in drug development rather than commercial sales, with a pipeline centered on targeted therapies for epilepsy, pain, bipolar disorder, and hearing-related conditions.

Name
Rapport Therapeutics, Inc. Common Stock
CEO
Abraham N. Ceesay
Website
www.rapportrx.com
Industry
Healthcare
Year Founded
2022
Employees
84

Today's Snapshot

AI-generated

RAPP started the session slightly lower at 43.87, while its sector was flat.

Trading Volume

Below 10d avg (271.3K)

18.4K

vs S&P 500 Today

Underperforming Market

-2.99%

Updated: September 15, 2026 at 14:39 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
The chart for RAPP shows a cautious sell bias as the stock trades near 42.81 while short- and medium-term moving averages sit above the price, even though the 200-day averages remain well below, indicating longer-term support. Momentum measures are weak with a negative MACD and a falling momentum oscillator, while the RSI sits in the lower range and ADX near the mid-20s signals a modest directional trend. On-balance volume is negative, suggesting distribution, while average true range implies moderate volatility. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$36.42 - $45.98
    Sell
  • RSI (14)37.36
    Neutral
  • Stochastic %K (14, 3, 3)8.03
    Buy
  • MACD Level (12, 26)-0.52
    Sell

Peers & Related Assets

NRIXNurix Therapeutics, Inc.
$25.52+1.7%
KODKodiak Sciences Inc.
$33.14+0.8%
URGNUroGen Pharma Ltd.
$42.64+0.8%
XNCRXencor, Inc.
$24.53+0.5%
SEPNSepterna Inc
$39.55+2.7%
ANABAnaptysBio, Inc.
$54.11+0.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.